urea has been researched along with Alzheimer Disease in 46 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pimavanserin-treated patients with ≥50% response in psychotic symptoms (n = 44) showed a greater improvement in agitation and aggression symptoms on the NPI-NH domain C (week six, least squares mean [LSM] difference = -3." | 9.34 | Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. ( Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S, 2020) |
| "To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhibitors (ACEis)." | 7.83 | Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease. ( Berretta, JM; Cardoso Smith, M; Ferreira Bertolucci, PH; Ferreira de Oliveira, F; Suchi Chen, E, 2016) |
| "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0." | 6.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "Pimavanserin-treated patients with ≥50% response in psychotic symptoms (n = 44) showed a greater improvement in agitation and aggression symptoms on the NPI-NH domain C (week six, least squares mean [LSM] difference = -3." | 5.34 | Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. ( Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S, 2020) |
| "To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhibitors (ACEis)." | 3.83 | Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease. ( Berretta, JM; Cardoso Smith, M; Ferreira Bertolucci, PH; Ferreira de Oliveira, F; Suchi Chen, E, 2016) |
| "Dementia due to Parkinson's disease and Alzheimer's disease are associated with behavioural and psychological symptoms, including psychosis." | 3.01 | Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. ( Isaacson, SH; Pagan, F; Pahwa, R; Sabbagh, M; Small, GW; Torres-Yaghi, Y, 2023) |
| "Pimavanserin has a unique mechanism of action." | 3.01 | A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. ( Akın, M; Kurhan, F, 2023) |
| "Treatment with pimavanserin showed an acceptable tolerability profile." | 2.90 | Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. ( Ballard, C; Coate, B; Stankovic, S; Youakim, JM, 2019) |
| "Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson's disease." | 2.66 | New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. ( Cannavò, D; Caraci, F; Caruso, G; Drago, F; Leggio, GM; Salomone, S; Santagati, M, 2020) |
| "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0." | 2.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "Neuropsychiatric symptoms are common in Alzheimer's disease (AD) and other neurodegenerative disorders." | 2.52 | Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. ( Cummings, J; Zhong, K, 2015) |
| "A hallmark pathology of Alzheimer's disease (AD) is the construction of neurofibrillary tangles, which are made of hyperphosphorylated Tau." | 1.91 | Effective Reduction of Tau Amyloid Aggregates in the Presence of Cyclophilin from ( Akbari, V; Bijari, N; Karima, S; Khodarahmi, R; Mehrabi, M; Ojaghi, S; Ranjbar, S; Sankian, M, 2023) |
| "Alzheimer's disease is a severe brain illness that causes vast numbers of nerve cells in the brain to die, driven by the production and deposition of amyloid beta (Aβ) peptides." | 1.48 | Synergistic approaches unraveling regulation and aggregation of intrinsically disordered β-amyloids implicated in Alzheimer's disease. ( Grover, A; Kumari, A; Rajput, R; Shrivastava, N; Somvanshi, P, 2018) |
| "Remarkably, key transcripts related to Alzheimer's disease are affected." | 1.46 | Cholinergic Surveillance over Hippocampal RNA Metabolism and Alzheimer's-Like Pathology. ( Al-Onaizi, M; Barbash, S; Bekenstein, U; Fahnestock, M; Haberman, N; Hanin, G; Kish, MT; Kolisnyk, B; Prado, MAM; Prado, VF; Soreq, H; Soreq, L; Souza da Silva, J; Ule, J, 2017) |
| " Moreover, hERG and BBB-PAMPA assays presented safe cardiotoxicity and high CNS bioavailability profiles for 5x." | 1.46 | Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction. ( Elkamhawy, A; Hassan, AHE; Lee, J; Moon, B; Pae, AN; Park, BG; Park, HM; Park, JE; Ra, H; Roh, EJ, 2017) |
| "Treatment with ZJ43 or 2-PMPA prior to acquisition trials increased long-term memory in mGluR2, but not mGluR3, ko mice." | 1.46 | NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication. ( Balasubramanian, S; Bzdega, T; Craddock, KE; Der, EK; Hark, TJ; Janczura, KJ; Moussa, C; Neale, JH; O'Rourke, B; Olszewski, RT; Venzor, F, 2017) |
| "Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology." | 1.38 | Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. ( Bonhaus, DW; McFarland, K; Price, DL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (10.87) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 4 (8.70) | 29.6817 |
| 2010's | 24 (52.17) | 24.3611 |
| 2020's | 11 (23.91) | 2.80 |
| Authors | Studies |
|---|---|
| Sabbagh, M | 1 |
| Small, GW | 1 |
| Isaacson, SH | 1 |
| Torres-Yaghi, Y | 1 |
| Pagan, F | 1 |
| Pahwa, R | 1 |
| Ju, YH | 1 |
| Bhalla, M | 1 |
| Hyeon, SJ | 1 |
| Oh, JE | 1 |
| Yoo, S | 1 |
| Chae, U | 1 |
| Kwon, J | 1 |
| Koh, W | 1 |
| Lim, J | 1 |
| Park, YM | 1 |
| Lee, J | 3 |
| Cho, IJ | 1 |
| Lee, H | 1 |
| Ryu, H | 1 |
| Lee, CJ | 1 |
| Frame, AK | 1 |
| Cumming, RC | 1 |
| Arsiccio, A | 1 |
| Liu, X | 1 |
| Ganguly, P | 1 |
| Buratto, SK | 1 |
| Bowers, MT | 1 |
| Shea, JE | 1 |
| Mehrabi, M | 1 |
| Bijari, N | 1 |
| Akbari, V | 1 |
| Ranjbar, S | 1 |
| Karima, S | 1 |
| Sankian, M | 1 |
| Ojaghi, S | 1 |
| Khodarahmi, R | 1 |
| Kurhan, F | 1 |
| Akın, M | 1 |
| Kushwah, N | 1 |
| Jain, V | 1 |
| Yadav, D | 1 |
| Schmidt, M | 2 |
| Benek, O | 3 |
| Vinklarova, L | 2 |
| Hrabinova, M | 1 |
| Zemanova, L | 1 |
| Chribek, M | 1 |
| Kralova, V | 1 |
| Hroch, L | 3 |
| Dolezal, R | 2 |
| Lycka, A | 1 |
| Prchal, L | 1 |
| Jun, D | 1 |
| Aitken, L | 3 |
| Gunn-Moore, F | 2 |
| Kuca, K | 3 |
| Musilek, K | 3 |
| Caraci, F | 1 |
| Santagati, M | 1 |
| Caruso, G | 1 |
| Cannavò, D | 1 |
| Leggio, GM | 1 |
| Salomone, S | 1 |
| Drago, F | 1 |
| Ballard, CG | 1 |
| Coate, B | 3 |
| Abler, V | 1 |
| Stankovic, S | 4 |
| Foff, E | 2 |
| Gründer, G | 1 |
| Cumming, P | 1 |
| Alemi, M | 1 |
| Silva, SC | 1 |
| Santana, I | 1 |
| Cardoso, I | 1 |
| Jęśko, H | 1 |
| Lukiw, WJ | 1 |
| Wilkaniec, A | 1 |
| Cieślik, M | 1 |
| Gąssowska-Dobrowolska, M | 1 |
| Murawska, E | 1 |
| Hilgier, W | 1 |
| Adamczyk, A | 1 |
| Schneider, LS | 1 |
| Ballard, C | 3 |
| Banister, C | 1 |
| Khan, Z | 1 |
| Cummings, J | 3 |
| Demos, G | 1 |
| Youakim, JM | 2 |
| Owen, R | 2 |
| Kumari, A | 1 |
| Rajput, R | 1 |
| Shrivastava, N | 1 |
| Somvanshi, P | 1 |
| Grover, A | 1 |
| De Simone, E | 1 |
| Di Micco, L | 1 |
| La Manna, G | 1 |
| Di Iorio, B | 1 |
| Elkamhawy, A | 2 |
| Park, JE | 2 |
| Hassan, AHE | 2 |
| Pae, AN | 2 |
| Paik, S | 1 |
| Park, BG | 2 |
| Roh, EJ | 2 |
| Tariot, P | 1 |
| Youakim, J | 1 |
| Norton, J | 1 |
| McKelvie, BE | 1 |
| Hughes, RE | 1 |
| Major, LL | 1 |
| Smith, TK | 2 |
| Gunn-Moore, FJ | 1 |
| More, SS | 1 |
| Vartak, AP | 1 |
| Vince, R | 1 |
| Simões, AE | 1 |
| Pereira, DM | 1 |
| Amaral, JD | 1 |
| Nunes, AF | 1 |
| Gomes, SE | 1 |
| Rodrigues, PM | 1 |
| Lo, AC | 1 |
| D'Hooge, R | 1 |
| Steer, CJ | 1 |
| Thibodeau, SN | 1 |
| Borralho, PM | 1 |
| Rodrigues, CM | 1 |
| Weiler, M | 1 |
| Fukuda, A | 1 |
| Massabki, LH | 1 |
| Lopes, TM | 1 |
| Franco, AR | 1 |
| Damasceno, BP | 1 |
| Cendes, F | 1 |
| Balthazar, ML | 1 |
| Zhong, K | 1 |
| Kurt, BZ | 1 |
| Gazioglu, I | 1 |
| Basile, L | 1 |
| Sonmez, F | 1 |
| Ginex, T | 1 |
| Kucukislamoglu, M | 1 |
| Guccione, S | 1 |
| Guest, P | 1 |
| Soukup, O | 1 |
| Janockova, J | 1 |
| Musil, K | 1 |
| Dohnal, V | 1 |
| Kolisnyk, B | 1 |
| Al-Onaizi, M | 1 |
| Soreq, L | 1 |
| Barbash, S | 1 |
| Bekenstein, U | 1 |
| Haberman, N | 1 |
| Hanin, G | 1 |
| Kish, MT | 1 |
| Souza da Silva, J | 1 |
| Fahnestock, M | 1 |
| Ule, J | 1 |
| Soreq, H | 1 |
| Prado, VF | 1 |
| Prado, MAM | 1 |
| Ferreira de Oliveira, F | 1 |
| Berretta, JM | 1 |
| Suchi Chen, E | 1 |
| Cardoso Smith, M | 1 |
| Ferreira Bertolucci, PH | 1 |
| Ra, H | 1 |
| Moon, B | 1 |
| Park, HM | 1 |
| Olszewski, RT | 1 |
| Janczura, KJ | 1 |
| Bzdega, T | 1 |
| Der, EK | 1 |
| Venzor, F | 1 |
| O'Rourke, B | 1 |
| Hark, TJ | 1 |
| Craddock, KE | 1 |
| Balasubramanian, S | 1 |
| Moussa, C | 1 |
| Neale, JH | 1 |
| Cascalheira, JF | 1 |
| João, SS | 1 |
| Pinhanços, SS | 1 |
| Castro, R | 1 |
| Palmeira, M | 1 |
| Almeida, S | 1 |
| Faria, MC | 1 |
| Domingues, FC | 1 |
| Gozal, YM | 1 |
| Duong, DM | 1 |
| Gearing, M | 1 |
| Cheng, D | 1 |
| Hanfelt, JJ | 1 |
| Funderburk, C | 1 |
| Peng, J | 1 |
| Lah, JJ | 1 |
| Levey, AI | 1 |
| Hansmannel, F | 1 |
| Sillaire, A | 1 |
| Kamboh, MI | 1 |
| Lendon, C | 1 |
| Pasquier, F | 1 |
| Hannequin, D | 1 |
| Laumet, G | 1 |
| Mounier, A | 1 |
| Ayral, AM | 1 |
| DeKosky, ST | 1 |
| Hauw, JJ | 1 |
| Berr, C | 1 |
| Mann, D | 1 |
| Amouyel, P | 1 |
| Campion, D | 1 |
| Lambert, JC | 1 |
| Chen, YR | 1 |
| Huang, HB | 1 |
| Lo, CJ | 1 |
| Wang, CC | 1 |
| Su, CL | 1 |
| Liu, HT | 1 |
| Shiao, MS | 1 |
| Lin, TH | 1 |
| Chen, YC | 1 |
| Ngo, S | 1 |
| Guo, Z | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| McFarland, K | 1 |
| Maler, JM | 1 |
| Klafki, HW | 1 |
| Paul, S | 1 |
| Spitzer, P | 1 |
| Groemer, TW | 1 |
| Henkel, AW | 1 |
| Esselmann, H | 1 |
| Lewczuk, P | 1 |
| Kornhuber, J | 1 |
| Wiltfang, J | 1 |
| Selkoe, DJ | 1 |
| Ihara, Y | 2 |
| Salazar, FJ | 1 |
| Anderton, B | 1 |
| Köpke, E | 1 |
| Tung, YC | 1 |
| Shaikh, S | 1 |
| Alonso, AC | 1 |
| Iqbal, K | 1 |
| Grundke-Iqbal, I | 1 |
| Smith, MA | 1 |
| Siedlak, SL | 1 |
| Richey, PL | 1 |
| Nagaraj, RH | 1 |
| Elhammer, A | 1 |
| Perry, G | 1 |
| Ross, BD | 1 |
| Mori, H | 1 |
| Kondo, J | 1 |
| Montejo de Garcini, E | 2 |
| Avila, J | 2 |
| Carrascosa, JL | 1 |
| Correas, I | 1 |
| Nieto, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evidence-Based Supported Digital Intervention for Improving Wellbeing and Health of People Living in Care Homes and Care Home Staff (WHELD) During COVID-19: An RCT to Evaluate COVID-19 Adapted E-WHELD: Benefits and Cost-Effectiveness[NCT04590469] | 2,880 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | |||
| A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease[NCT02035553] | Phase 2 | 181 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| The PREVENTION Trial: Precision Recommendations for Environmental Variables, Exercise, Nutrition and Training Interventions to Optimize Neurocognition[NCT04082611] | 60 participants (Anticipated) | Interventional | 2019-07-12 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from Baseline to Day 43 in the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) psychosis score (Delusions [Domain A]+Hallucinations [Domain B]) in the Full Analysis Set (FAS). The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains. For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), The NPI-NH Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual domain scores, to yield a possible total score of 0 to 24. Lower scores correspond to less severity. A negative change score from baseline indicates improvement. (NCT02035553)
Timeframe: Day 43
| Intervention | Score on the NPI-NH scale (Least Squares Mean) |
|---|---|
| Placebo | -1.93 |
| Pimavanserin 40 mg | -3.76 |
8 reviews available for urea and Alzheimer Disease
| Article | Year |
|---|---|
Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders | 2023 |
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; United Stat | 2023 |
Osmolytes: A Possible Therapeutic Molecule for Ameliorating the Neurodegeneration Caused by Protein Misfolding and Aggregation.
Topics: Alzheimer Disease; Amino Acids; Amyloid beta-Peptides; Animals; Brain; Carbohydrate Metabolism; Drug | 2020 |
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Anxiety; Humans; Piperidines; Psychotic Disorders; Quinolon | 2020 |
[Protein carbamylation: what it is and why it concerns nephrologists].
Topics: Alzheimer Disease; Amino Acids; Amyloidosis; Anemia, Sickle Cell; Animals; Cardiovascular Diseases; | 2018 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Par | 2018 |
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
Topics: Alzheimer Disease; Apathy; Citalopram; Clinical Trials as Topic; Cognition Disorders; Humans; Mental | 2015 |
Real or imaginary? Human metabolism through nuclear magnetism.
Topics: Alzheimer Disease; Animals; Brain; Down Syndrome; Glutamic Acid; History, 20th Century; Humans; In V | 2000 |
3 trials available for urea and Alzheimer Disease
35 other studies available for urea and Alzheimer Disease
| Article | Year |
|---|---|
Astrocytic urea cycle detoxifies Aβ-derived ammonia while impairing memory in Alzheimer's disease.
Topics: Alzheimer Disease; Ammonia; Amyloid beta-Peptides; Astrocytes; Humans; Hydrogen Peroxide; Memory Dis | 2022 |
Using the urea cycle to shift astrocytes from harmful to helpful in Alzheimer's disease.
Topics: Alzheimer Disease; Astrocytes; Brain; Humans; Urea | 2022 |
Effect of Cosolutes on the Aggregation of a Tau Fragment: A Combined Experimental and Simulation Approach.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Alzheimer Disease; Humans; Molecular Dynamics Simulation; tau Pro | 2023 |
Effective Reduction of Tau Amyloid Aggregates in the Presence of Cyclophilin from
Topics: Allergens; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Cyclophilins; Pollen; Proline; tau Pro | 2023 |
Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer's Disease Treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Benzothiazoles; Enzyme Activation; Enzyme Inhib | 2020 |
Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT
Topics: Alzheimer Disease; Animals; Brain; Depression; Disease Models, Animal; Mice; Mice, Transgenic; Pharm | 2021 |
Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barri | 2017 |
Altered Expression of Urea Cycle Enzymes in Amyloid-β Protein Precursor Overexpressing PC12 Cells and in Sporadic Alzheimer's Disease Brain.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Arginase; Arginine; Argininosuccinate Ly | 2018 |
Pimavanserin for patients with Alzheimer's disease psychosis.
Topics: Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychotic Disorders; Urea | 2018 |
Synergistic approaches unraveling regulation and aggregation of intrinsically disordered β-amyloids implicated in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Intrinsically Disordered Proteins; Methylamines; P | 2018 |
Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cell Survival; Dose-Response Relationship, Drug | 2018 |
Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment.
Topics: 17-Hydroxysteroid Dehydrogenases; Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Cell Lin | 2019 |
Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Brain; Coenzymes; Disease Model | 2013 |
Efficient recovery of proteins from multiple source samples after TRIzol(®) or TRIzol(®)LS RNA extraction and long-term storage.
Topics: Adenoma, Villous; Alzheimer Disease; Animals; Brain; Carcinoma; Cells, Cultured; Chloroform; Colonic | 2013 |
Default mode, executive function, and language functional connectivity networks are compromised in mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Carbamide Peroxide; Cognitive Dysf | 2014 |
Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzofurans; Butyrylcholinesterase; | 2015 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cel | 2016 |
Cholinergic Surveillance over Hippocampal RNA Metabolism and Alzheimer's-Like Pathology.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anima | 2017 |
Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Angiotensin-Converting Enzyme Inhi | 2016 |
Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cyclosporine; Dru | 2017 |
NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
Topics: Alcoholic Intoxication; Alzheimer Disease; Animals; Disease Models, Animal; Ethanol; Excitatory Amin | 2017 |
Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; C-Reactive Protein; Case-Control Studies; Estradiol; Fem | 2009 |
Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease.
Topics: Alzheimer Disease; Chromatography, Liquid; Detergents; Frontotemporal Lobar Degeneration; Humans; Mo | 2009 |
Is the urea cycle involved in Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Arginase; Brain; Case-Control Studies; Chi-Squa | 2010 |
Aβ40(L17A/F19A) mutant diminishes the aggregation and neurotoxicity of Aβ40.
Topics: Alanine; Alzheimer Disease; Amino Acid Substitution; Amyloid beta-Peptides; Animals; Cell Survival; | 2011 |
Key residues for the oligomerization of Aβ42 protein in Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Substitution; Amyloid beta-Peptides; Chaperonin 10; Cysteine; Humans; | 2011 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disea | 2012 |
Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Electrophoresis, Gel, Two-Dimensional; Humans; Middle Aged | 2007 |
Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea.
Topics: Alzheimer Disease; Cerebral Cortex; Cytoskeleton; Dementia; gamma-Glutamyltransferase; Humans; Micro | 1982 |
Untangling insoluble filaments.
Topics: Acyltransferases; Alzheimer Disease; Dementia; Guanidine; Guanidines; Humans; Neurofibrils; Octoxyno | 1983 |
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Chromatography, Affinity; Chromatography, Ion Exc | 1993 |
Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkalies; Alzheimer Disease; Cell Fractionation; Cross-L | 1996 |
Ubiquitin is a component of paired helical filaments in Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Antibodies, Monoclonal; Chromatography, High Pressure Liquid | 1987 |
In vitro conditions for the self-polymerization of the microtubule-associated protein, tau factor.
Topics: Alzheimer Disease; Animals; Glutaminase; Gold; Humans; Hydrogen-Ion Concentration; Immunologic Tests | 1987 |
Tau factor polymers are similar to paired helical filaments of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; DNA Polymerase III; Humans; Immunohistochemistry; Microscopy, Electron; | 1988 |